Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
67%(6 trials)

Phase Distribution

Ph phase_4
1
11%
Ph phase_2
1
11%
Ph phase_3
7
78%

Phase Distribution

0

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
7(77.8%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (11.1%)
Phase 37 (77.8%)
Phase 41 (11.1%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_4

Hepatitis B Vaccination in Infants

NCT01896596
completedphase_2

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

NCT01171989
completedphase_3

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

NCT00463437
completedphase_3

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

NCT01839188
completedphase_3

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

NCT00443846
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01896596Phase 4

Hepatitis B Vaccination in Infants

Completed
NCT01171989Phase 2

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

Completed
NCT00463437Phase 3

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Completed
NCT01839188Phase 3

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Completed
NCT00443846Phase 3

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Completed
NCT01839175Phase 3

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Completed
NCT00322335Phase 3

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Completed
NCT00327184Phase 3

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

Completed
NCT00384059Phase 3

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9